{
    "info": {
        "nct_id": "NCT06834373",
        "official_title": "Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)",
        "inclusion_criteria": "* Age ≥ 18 years\n* Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification including patients with diseases listed below with relapsed, progressive and/or refractory disease (Cheson et al. 2014) following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted:\n\n  * Diffuse large B-cell lymphoma not otherwise specified (NOS) including:\n\n    * Transformed lymphoma\n    * Germinal center B-cell type\n    * Activated B-cell type\n  * High-grade B-cell lymphoma (HGBCL), NOS\n  * High grade B-cell lymphoma with MYC and BCL2 translocation\n  * Primary mediastinal (thymic) large B-cell lymphoma\n  * Grade 3B follicular lymphoma\n  * T-cell/histiocyte-rich large B-cell lymphoma\n  * Large B-cell lymphoma with IRF4 rearrangement\n  * Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type\n  * Epstein-Barr virus (EBV) positive DLBCL, NOS\n  * DLBCL associated with chronic inflammation\n  * Intravascular large B-cell lymphoma\n  * ALK positive large B-cell lymphoma\n  * NOTE: Richters transformation patients are excluded\n* Measurable disease by PET-CT with at least one lymph node or other type of lesion that has a size > 1.5 cm in the transverse diameter, as defined by Lugano classification\n\n  * NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible\n* Patient is potentially eligible for CAR-T therapy as determined by treating physician\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2\n* Hemoglobin > 7.0 g/dL (obtained ≤ 14 days prior to registration)\n* Absolute neutrophil count (ANC) ≥ 1000/mcL (obtained ≤ 14 days prior to registration); growth factor support allowed at physician discretion\n* Platelet count ≥ 75,000/mcL (obtained ≤ 14 days prior to registration)\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration); if total bilirubin is > 1.5 ULN, direct bilirubin must be normal\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)\n* Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)\n* Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282:\n\n  * A negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening (between 10 to 14 days prior to cycle 1 day 1)\n  * A negative serum or urine pregnancy test (investigator's discretion) within 24 hours prior to cycle 1 day 1 of study treatment\n* Provide written informed consent\n* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any of the following because this study involves an investigational agent that has known genotoxic, mutagenic, and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n* Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception\n\n  * Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or postovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual contact during the following time periods related to this study:\n  * For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide\n  * Examples of highly effective methods of contraception:\n\n    * Intrauterine device (IUD)\n    * Hormonal (birth control pills, injections, implants, levonorgestrel-releasing intrauterine system [IUS], medroxyprogesterone acetate depot injections, ovulation inhibitory\n    * Progesterone-only pills [e.g., desogestrel])\n    * Tubal ligation\n    * Partner's vasectomy\n  * Examples of additional effective methods:\n\n    * Male condom\n    * Diaphragm\n    * Cervical cap\n  * Persons who can father a child unwilling to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or post-ovulation methods] and withdrawal are not acceptable methods of contraception.) or unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy\n  * Persons who can father a child and are unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide\n* Life expectancy < 3 months\n* Any of the following prior therapies:\n\n  * Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration\n  * Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter\n\n    * Exception: Monoclonal and bispecific antibodies is acceptable\n  * Prior therapy with golcadomide ≤ 4 weeks prior to registration\n  * Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration. If subject had autologous SCT > 3 months prior to the start of registration, any treatment-related toxicity is unresolved (grade > 1)\n  * Major surgery ≤ 3 weeks prior to registration\n  * Chemotherapy ≤ 2 weeks prior to registration\n  * Concomitant radiation therapy; local palliative radiotherapy is permitted\n* Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Impaired cardiac function or clinically significant cardiac diseases including, but not limited to:\n\n  * Symptomatic congestive heart failure\n  * History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n* Uncontrolled intercurrent non-cardiac illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Psychiatric illness/social situations\n  * Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease [COPD])\n  * Any other conditions that would limit compliance with study requirements\n* Subject had prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration. If subject had prior allogeneic SCT > 6 months prior to registration, any treatment-related toxicity is unresolved (grade >1)\n* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy, as there is currently no safety data in HIV positive patients\n* Subject has known chronic active hepatitis B or C virus (HBV/HCV) infection\n\n  * Exception: Patients with HBV and an undetectable viral load who are on suppressive therapy and/or those with HCV and an undetectable viral load are allowed\n* Concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration\n* Receiving any other investigational agent which would be considered as a treatment for lymphoma.\n\n  * Exception: Corticosteroids are allowed\n* Active second malignancy requiring treatment that would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy\n* History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia. Patients with a history of deep vein thrombosis (DVT)/pulmonary embolism (PE) or thrombophilia may still participate if they are willing to be on full anticoagulation during treatment. Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses. The rationale for this requirement is that golcadomide therapy is associated with an increased risk of thrombosis. Patients with no history of DVT/PE or thrombophilia are not required to take anticoagulation and/or anti-platelet prophylaxis\n\n  * NOTE: If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin. This is due to an increased risk of thrombosis in patients treated with golcadomide without prophylaxis\n* Live COVID-19 vaccine administered ≤ 28 days prior to registration",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Transformed lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "Transformed lymphoma",
                        "criterion": "transformed lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Transformed lymphoma",
                        "criterion": "transformed lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ALK positive large B-cell lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "ALK positive large B-cell lymphoma",
                        "criterion": "large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "ALK positivity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ALK positive large B-cell lymphoma",
                        "criterion": "large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "ALK positivity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Provide written informed consent",
                "criterions": [
                    {
                        "exact_snippets": "Provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "provided",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Provide written informed consent",
                        "criterion": "informed consent",
                        "requirement": {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hemoglobin > 7.0 g/dL (obtained ≤ 14 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin > 7.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 7.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained ≤ 14 days prior to registration",
                        "criterion": "hemoglobin measurement date",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin > 7.0 g/dL",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 7.0,
                                "unit": "g/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained ≤ 14 days prior to registration",
                        "criterion": "hemoglobin measurement date",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Primary mediastinal (thymic) large B-cell lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "Primary mediastinal (thymic) large B-cell lymphoma",
                        "criterion": "primary mediastinal (thymic) large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Primary mediastinal (thymic) large B-cell lymphoma",
                        "criterion": "primary mediastinal (thymic) large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* NOTE: Richters transformation patients are excluded",
                "criterions": [
                    {
                        "exact_snippets": "Richters transformation patients are excluded",
                        "criterion": "Richter's transformation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Richters transformation patients are excluded",
                        "criterion": "Richter's transformation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Diffuse large B-cell lymphoma not otherwise specified (NOS) including:",
                "criterions": [
                    {
                        "exact_snippets": "Diffuse large B-cell lymphoma not otherwise specified (NOS)",
                        "criterion": "diffuse large B-cell lymphoma (NOS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Diffuse large B-cell lymphoma not otherwise specified (NOS)",
                        "criterion": "diffuse large B-cell lymphoma (NOS)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Germinal center B-cell type",
                "criterions": [
                    {
                        "exact_snippets": "Germinal center B-cell type",
                        "criterion": "germinal center B-cell type",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Germinal center B-cell type",
                        "criterion": "germinal center B-cell type",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* High-grade B-cell lymphoma (HGBCL), NOS",
                "criterions": [
                    {
                        "exact_snippets": "High-grade B-cell lymphoma (HGBCL), NOS",
                        "criterion": "High-grade B-cell lymphoma, not otherwise specified (HGBCL, NOS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "High-grade B-cell lymphoma (HGBCL), NOS",
                        "criterion": "High-grade B-cell lymphoma, not otherwise specified (HGBCL, NOS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Measurable disease by PET-CT with at least one lymph node or other type of lesion that has a size > 1.5 cm in the transverse diameter, as defined by Lugano classification",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease by PET-CT",
                        "criterion": "disease measurability by PET-CT",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at least one lymph node or other type of lesion that has a size > 1.5 cm in the transverse diameter",
                        "criterion": "lymph node or other lesion size (transverse diameter)",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease by PET-CT",
                        "criterion": "disease measurability by PET-CT",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at least one lymph node or other type of lesion that has a size > 1.5 cm in the transverse diameter",
                        "criterion": "lymph node or other lesion size (transverse diameter)",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration); if total bilirubin is > 1.5 ULN, direct bilirubin must be normal",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "≤ 14 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "if total bilirubin is > 1.5 ULN, direct bilirubin must be normal",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": "normal"
                        }
                    },
                    {
                        "exact_snippets": "if total bilirubin is > 1.5 ULN, direct bilirubin must be normal",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "conditional_on",
                            "expected_value": "total bilirubin > 1.5 ULN"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to registration)",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "measurement_timeframe",
                                    "expected_value": "≤ 14 days prior to registration"
                                }
                            }
                        ]
                    },
                    {
                        "condition": {
                            "exact_snippets": "if total bilirubin is > 1.5 ULN, direct bilirubin must be normal",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "conditional_on",
                                "expected_value": "total bilirubin > 1.5 ULN"
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "if total bilirubin is > 1.5 ULN, direct bilirubin must be normal",
                            "criterion": "direct bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": "normal"
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at screening (between 10 to 14 days prior to cycle 1 day 1)",
                "criterions": [
                    {
                        "exact_snippets": "A negative serum pregnancy test",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "sensitivity of at least 25 mIU/mL",
                        "criterion": "serum pregnancy test sensitivity",
                        "requirement": {
                            "requirement_type": "sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "mIU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at screening (between 10 to 14 days prior to cycle 1 day 1)",
                        "criterion": "timing of serum pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "between 10 to 14 days prior to cycle 1 day 1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A negative serum pregnancy test",
                        "criterion": "serum pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "sensitivity of at least 25 mIU/mL",
                        "criterion": "serum pregnancy test sensitivity",
                        "requirement": {
                            "requirement_type": "sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "mIU/mL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at screening (between 10 to 14 days prior to cycle 1 day 1)",
                        "criterion": "timing of serum pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "between 10 to 14 days prior to cycle 1 day 1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Large B-cell lymphoma with IRF4 rearrangement",
                "criterions": [
                    {
                        "exact_snippets": "Large B-cell lymphoma",
                        "criterion": "Large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "IRF4 rearrangement",
                        "criterion": "IRF4 rearrangement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Large B-cell lymphoma",
                        "criterion": "Large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "IRF4 rearrangement",
                        "criterion": "IRF4 rearrangement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Intravascular large B-cell lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "Intravascular large B-cell lymphoma",
                        "criterion": "intravascular large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Intravascular large B-cell lymphoma",
                        "criterion": "intravascular large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* DLBCL associated with chronic inflammation",
                "criterions": [
                    {
                        "exact_snippets": "DLBCL associated with chronic inflammation",
                        "criterion": "DLBCL (Diffuse Large B-Cell Lymphoma)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "DLBCL associated with chronic inflammation",
                        "criterion": "chronic inflammation",
                        "requirement": {
                            "requirement_type": "association with DLBCL",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "DLBCL associated with chronic inflammation",
                        "criterion": "DLBCL (Diffuse Large B-Cell Lymphoma)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "DLBCL associated with chronic inflammation",
                        "criterion": "chronic inflammation",
                        "requirement": {
                            "requirement_type": "association with DLBCL",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282:",
                "criterions": [
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "number of tests",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "tests"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "verification",
                            "expected_value": "verified by the investigator"
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting CC-99282"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "number of tests",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "tests"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "verification",
                            "expected_value": "verified by the investigator"
                        }
                    },
                    {
                        "exact_snippets": "Have 2 negative pregnancy tests as verified by the investigator prior to starting CC-99282",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to starting CC-99282"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Grade 3B follicular lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "Grade 3B follicular lymphoma",
                        "criterion": "follicular lymphoma",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "3B"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Grade 3B follicular lymphoma",
                        "criterion": "follicular lymphoma",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "3B"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type",
                "criterions": [
                    {
                        "exact_snippets": "Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type",
                        "criterion": "primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type",
                        "criterion": "primary cutaneous diffuse large B-cell lymphoma (DLBCL), leg type",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                "criterions": [
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        }
                    },
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "active monitoring phase of the study"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "location",
                            "expected_value": "enrolling institution"
                        }
                    },
                    {
                        "exact_snippets": "Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)",
                        "criterion": "willingness to return for follow-up",
                        "requirement": {
                            "requirement_type": "phase",
                            "expected_value": "active monitoring phase of the study"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Epstein-Barr virus (EBV) positive DLBCL, NOS",
                "criterions": [
                    {
                        "exact_snippets": "Epstein-Barr virus (EBV) positive",
                        "criterion": "Epstein-Barr virus (EBV) status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "DLBCL, NOS",
                        "criterion": "diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Epstein-Barr virus (EBV) positive",
                        "criterion": "Epstein-Barr virus (EBV) status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "DLBCL, NOS",
                        "criterion": "diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patient is potentially eligible for CAR-T therapy as determined by treating physician",
                "criterions": [
                    {
                        "exact_snippets": "potentially eligible for CAR-T therapy",
                        "criterion": "CAR-T therapy eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as determined by treating physician",
                        "criterion": "treating physician determination",
                        "requirement": {
                            "requirement_type": "determination",
                            "expected_value": "treating physician"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "potentially eligible for CAR-T therapy",
                        "criterion": "CAR-T therapy eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "as determined by treating physician",
                        "criterion": "treating physician determination",
                        "requirement": {
                            "requirement_type": "determination",
                            "expected_value": "treating physician"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "time of measurement",
                            "expected_value": "≤ 14 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "aspartate transaminase (AST) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                        "criterion": "aspartate transaminase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "aspartate transaminase (AST) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                        "criterion": "aspartate transaminase (AST) level",
                        "requirement": {
                            "requirement_type": "time of measurement",
                            "expected_value": "≤ 14 days prior to registration"
                        }
                    },
                    {
                        "exact_snippets": "ALT ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                        "criterion": "alanine aminotransferase (ALT) level with parenchymal liver involvement with lymphoma",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                        "criterion": "alanine aminotransferase (ALT) level with parenchymal liver involvement with lymphoma",
                        "requirement": {
                            "requirement_type": "condition",
                            "expected_value": "evidence of parenchymal liver involvement with lymphoma"
                        }
                    },
                    {
                        "exact_snippets": "AST ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                        "criterion": "aspartate transaminase (AST) level with parenchymal liver involvement with lymphoma",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                        "criterion": "aspartate transaminase (AST) level with parenchymal liver involvement with lymphoma",
                        "requirement": {
                            "requirement_type": "condition",
                            "expected_value": "evidence of parenchymal liver involvement with lymphoma"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "condition": {
                                    "exact_snippets": "ALT ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                                    "criterion": "alanine aminotransferase (ALT) level with parenchymal liver involvement with lymphoma",
                                    "requirement": {
                                        "requirement_type": "condition",
                                        "expected_value": "evidence of parenchymal liver involvement with lymphoma"
                                    }
                                },
                                "then_criteria": {
                                    "exact_snippets": "ALT ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                                    "criterion": "alanine aminotransferase (ALT) level with parenchymal liver involvement with lymphoma",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": 5,
                                                    "unit": "x ULN"
                                                }
                                            ]
                                        }
                                    }
                                },
                                "else_criteria": {
                                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                                    "criterion": "alanine aminotransferase (ALT) level",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": 2.5,
                                                    "unit": "x ULN"
                                                }
                                            ]
                                        }
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                                "criterion": "alanine aminotransferase (ALT) level",
                                "requirement": {
                                    "requirement_type": "time of measurement",
                                    "expected_value": "≤ 14 days prior to registration"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "condition": {
                                    "exact_snippets": "AST ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                                    "criterion": "aspartate transaminase (AST) level with parenchymal liver involvement with lymphoma",
                                    "requirement": {
                                        "requirement_type": "condition",
                                        "expected_value": "evidence of parenchymal liver involvement with lymphoma"
                                    }
                                },
                                "then_criteria": {
                                    "exact_snippets": "AST ... (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma)",
                                    "criterion": "aspartate transaminase (AST) level with parenchymal liver involvement with lymphoma",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": 5,
                                                    "unit": "x ULN"
                                                }
                                            ]
                                        }
                                    }
                                },
                                "else_criteria": {
                                    "exact_snippets": "aspartate transaminase (AST) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                                    "criterion": "aspartate transaminase (AST) level",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": "<=",
                                                    "value": 2.5,
                                                    "unit": "x ULN"
                                                }
                                            ]
                                        }
                                    }
                                }
                            },
                            {
                                "exact_snippets": "aspartate transaminase (AST) ... ≤ 2.5 x ULN (≤ 5 x ULN if there is evidence of parenchymal liver involvement with lymphoma) (obtained ≤ 14 days prior to registration)",
                                "criterion": "aspartate transaminase (AST) level",
                                "requirement": {
                                    "requirement_type": "time of measurement",
                                    "expected_value": "≤ 14 days prior to registration"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Activated B-cell type",
                "criterions": [
                    {
                        "exact_snippets": "Activated B-cell type",
                        "criterion": "B-cell type",
                        "requirement": {
                            "requirement_type": "activation status",
                            "expected_value": "activated"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Activated B-cell type",
                        "criterion": "B-cell type",
                        "requirement": {
                            "requirement_type": "activation status",
                            "expected_value": "activated"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* T-cell/histiocyte-rich large B-cell lymphoma",
                "criterions": [
                    {
                        "exact_snippets": "T-cell/histiocyte-rich large B-cell lymphoma",
                        "criterion": "T-cell/histiocyte-rich large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "T-cell/histiocyte-rich large B-cell lymphoma",
                        "criterion": "T-cell/histiocyte-rich large B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible",
                "criterions": [
                    {
                        "exact_snippets": "Tumor lesions in a previously irradiated area are not considered measurable disease",
                        "criterion": "tumor lesions in previously irradiated area",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Disease that is measurable by physical examination only is not eligible",
                        "criterion": "disease measurable by physical examination only",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Tumor lesions in a previously irradiated area are not considered measurable disease",
                        "criterion": "tumor lesions in previously irradiated area",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Disease that is measurable by physical examination only is not eligible",
                        "criterion": "disease measurable by physical examination only",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Chemotherapy ≤ 2 weeks prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Chemotherapy ≤ 2 weeks prior to registration",
                        "criterion": "chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Chemotherapy ≤ 2 weeks prior to registration",
                        "criterion": "chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cervical cap",
                "criterions": [
                    {
                        "exact_snippets": "Cervical cap",
                        "criterion": "cervical cap",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cervical cap",
                        "criterion": "cervical cap",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Receiving any other investigational agent which would be considered as a treatment for lymphoma.",
                "criterions": [
                    {
                        "exact_snippets": "Receiving any other investigational agent which would be considered as a treatment for lymphoma",
                        "criterion": "receipt of other investigational agent for lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Receiving any other investigational agent which would be considered as a treatment for lymphoma",
                        "criterion": "receipt of other investigational agent for lymphoma",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant radiation therapy; local palliative radiotherapy is permitted",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant radiation therapy",
                        "criterion": "concomitant radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "local palliative radiotherapy is permitted",
                        "criterion": "local palliative radiotherapy",
                        "requirement": {
                            "requirement_type": "permission",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concomitant radiation therapy",
                        "criterion": "concomitant radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "local palliative radiotherapy is permitted",
                        "criterion": "local palliative radiotherapy",
                        "requirement": {
                            "requirement_type": "permission",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Life expectancy < 3 months",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy < 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy < 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Symptomatic congestive heart failure",
                "criterions": [
                    {
                        "exact_snippets": "Symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant persons",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant persons",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Pregnant persons",
                    "criterion": "pregnancy status",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Unstable angina pectoris",
                "criterions": [
                    {
                        "exact_snippets": "Unstable angina pectoris",
                        "criterion": "unstable angina pectoris",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Unstable angina pectoris",
                    "criterion": "unstable angina pectoris",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Psychiatric illness/social situations",
                "criterions": [
                    {
                        "exact_snippets": "Psychiatric illness",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situations",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Psychiatric illness",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "social situations",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled intercurrent non-cardiac illness including, but not limited to:",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent non-cardiac illness",
                        "criterion": "non-cardiac illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled intercurrent non-cardiac illness",
                        "criterion": "non-cardiac illness",
                        "requirement": {
                            "requirement_type": "intercurrent",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent non-cardiac illness",
                        "criterion": "non-cardiac illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled intercurrent non-cardiac illness",
                        "criterion": "non-cardiac illness",
                        "requirement": {
                            "requirement_type": "intercurrent",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Persons of childbearing potential (and persons able to father a child) who are unwilling to employ adequate contraception",
                "criterions": [
                    {
                        "exact_snippets": "Persons of childbearing potential (and persons able to father a child)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "persons of childbearing potential or persons able to father a child"
                        }
                    },
                    {
                        "exact_snippets": "unwilling to employ adequate contraception",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "willingness to use adequate contraception",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Persons of childbearing potential (and persons able to father a child)",
                        "criterion": "reproductive potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "persons of childbearing potential or persons able to father a child"
                        }
                    },
                    {
                        "exact_snippets": "unwilling to employ adequate contraception",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "willingness to use adequate contraception",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Live COVID-19 vaccine administered ≤ 28 days prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Live COVID-19 vaccine administered ≤ 28 days prior to registration",
                        "criterion": "live COVID-19 vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Live COVID-19 vaccine administered ≤ 28 days prior to registration",
                        "criterion": "live COVID-19 vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration before registration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Tubal ligation",
                "criterions": [
                    {
                        "exact_snippets": "Tubal ligation",
                        "criterion": "tubal ligation",
                        "requirement": {
                            "requirement_type": "history/presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Tubal ligation",
                    "criterion": "tubal ligation",
                    "requirement": {
                        "requirement_type": "history/presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",
                "criterions": [
                    {
                        "exact_snippets": "History of myocardial infarction ≤ 6 months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "requires_ongoing_maintenance_therapy_for_life_threatening_ventricular_arrhythmias",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of myocardial infarction ≤ 6 months",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "requires_ongoing_maintenance_therapy_for_life_threatening_ventricular_arrhythmias",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter",
                "criterions": [
                    {
                        "exact_snippets": "Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter",
                        "criterion": "prior systemic anti-cancer treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to registration, whichever is shorter",
                        "criterion": "prior systemic anti-cancer treatment",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active second malignancy requiring treatment that would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy",
                "criterions": [
                    {
                        "exact_snippets": "Active second malignancy requiring treatment",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active second malignancy requiring treatment",
                        "criterion": "second malignancy",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy",
                        "criterion": "potential interference with assessment or interpretation",
                        "requirement": {
                            "requirement_type": "interference with assessment of response of primary cancer",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy",
                        "criterion": "potential interference with assessment or interpretation",
                        "requirement": {
                            "requirement_type": "interference with interpretation of safety of protocol therapy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active second malignancy requiring treatment",
                                "criterion": "second malignancy",
                                "requirement": {
                                    "requirement_type": "activity status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Active second malignancy requiring treatment",
                                "criterion": "second malignancy",
                                "requirement": {
                                    "requirement_type": "treatment requirement",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy",
                                "criterion": "potential interference with assessment or interpretation",
                                "requirement": {
                                    "requirement_type": "interference with assessment of response of primary cancer",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "would interfere with the assessment of the response of the primary cancer or interpretation of the safety of this protocol therapy",
                                "criterion": "potential interference with assessment or interpretation",
                                "requirement": {
                                    "requirement_type": "interference with interpretation of safety of protocol therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cardiac arrhythmia",
                "criterions": [
                    {
                        "exact_snippets": "Cardiac arrhythmia",
                        "criterion": "cardiac arrhythmia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Examples of highly effective methods of contraception:",
                "criterions": [
                    {
                        "exact_snippets": "Examples of highly effective methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": "highly effective"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Examples of highly effective methods of contraception",
                    "criterion": "contraception method",
                    "requirement": {
                        "requirement_type": "effectiveness",
                        "expected_value": "highly effective"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Nursing persons",
                "criterions": [
                    {
                        "exact_snippets": "Nursing persons",
                        "criterion": "nursing status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "nursing"
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Nursing persons",
                    "criterion": "nursing status",
                    "requirement": {
                        "requirement_type": "status",
                        "expected_value": "nursing"
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration",
                        "criterion": "concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers",
                        "requirement": {
                            "requirement_type": "timing before study treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers within 14 days or 5 half-lives, whichever is longer before the study treatment administration",
                        "criterion": "concurrent administration of strong or moderate CYP3A4/5 inhibitors and inducers",
                        "requirement": {
                            "requirement_type": "timing before study treatment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subject has known chronic active hepatitis B or C virus (HBV/HCV) infection",
                "criterions": [
                    {
                        "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": "chronic active"
                        }
                    },
                    {
                        "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": "chronic active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": "chronic active"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "known chronic active hepatitis B or C virus (HBV/HCV) infection",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "chronicity",
                                    "expected_value": "chronic active"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Exception: Corticosteroids are allowed",
                "criterions": [
                    {
                        "exact_snippets": "Corticosteroids are allowed",
                        "criterion": "corticosteroid use",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Corticosteroids are allowed",
                            "criterion": "corticosteroid use",
                            "requirement": {
                                "requirement_type": "allowance",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prior therapy with golcadomide ≤ 4 weeks prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Prior therapy with golcadomide ≤ 4 weeks prior to registration",
                        "criterion": "prior therapy with golcadomide",
                        "requirement": {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior therapy with golcadomide ≤ 4 weeks prior to registration",
                        "criterion": "prior therapy with golcadomide",
                        "requirement": {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any other conditions that would limit compliance with study requirements",
                "criterions": [
                    {
                        "exact_snippets": "Any other conditions that would limit compliance with study requirements",
                        "criterion": "other conditions limiting compliance",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any other conditions that would limit compliance with study requirements",
                    "criterion": "other conditions limiting compliance",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": false
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any of the following prior therapies:",
                "criterions": [
                    {
                        "exact_snippets": "Any of the following prior therapies",
                        "criterion": "prior therapies",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Any of the following prior therapies",
                    "criterion": "prior therapies",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Partner's vasectomy",
                "criterions": [
                    {
                        "exact_snippets": "Partner's vasectomy",
                        "criterion": "partner's vasectomy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": "vasectomy"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Partner's vasectomy",
                        "criterion": "partner's vasectomy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": "vasectomy"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Impaired cardiac function or clinically significant cardiac diseases including, but not limited to:",
                "criterions": [
                    {
                        "exact_snippets": "Impaired cardiac function",
                        "criterion": "cardiac function",
                        "requirement": {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant cardiac diseases",
                        "criterion": "cardiac diseases",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Impaired cardiac function",
                        "criterion": "cardiac function",
                        "requirement": {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "clinically significant cardiac diseases",
                        "criterion": "cardiac diseases",
                        "requirement": {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Exception: Patients with HBV and an undetectable viral load who are on suppressive therapy and/or those with HCV and an undetectable viral load are allowed",
                "criterions": [
                    {
                        "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                        "criterion": "hepatitis B virus (HBV) infection",
                        "requirement": {
                            "requirement_type": "suppressive therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "those with HCV and an undetectable viral load",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "those with HCV and an undetectable viral load",
                        "criterion": "hepatitis C virus (HCV) infection",
                        "requirement": {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "viral load",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "detectable"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Patients with HBV and an undetectable viral load who are on suppressive therapy",
                                "criterion": "hepatitis B virus (HBV) infection",
                                "requirement": {
                                    "requirement_type": "suppressive therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "those with HCV and an undetectable viral load",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "those with HCV and an undetectable viral load",
                                "criterion": "hepatitis C virus (HCV) infection",
                                "requirement": {
                                    "requirement_type": "viral load",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "detectable"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Intrauterine device (IUD)",
                "criterions": [
                    {
                        "exact_snippets": "Intrauterine device (IUD)",
                        "criterion": "intrauterine device (IUD)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Intrauterine device (IUD)",
                    "criterion": "intrauterine device (IUD)",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Diaphragm",
                "criterions": [
                    {
                        "exact_snippets": "Diaphragm",
                        "criterion": "diaphragm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Diaphragm",
                        "criterion": "diaphragm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Male condom",
                "criterions": [
                    {
                        "exact_snippets": "Male condom",
                        "criterion": "male condom",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Male condom",
                    "criterion": "male condom",
                    "requirement": {
                        "requirement_type": "use",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Any of the following because this study involves an investigational agent that has known genotoxic, mutagenic, and teratogenic effects:",
                "criterions": [
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "genotoxicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "mutagenicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "teratogenicity",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "genotoxicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "mutagenicity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "investigational agent that has known genotoxic ... mutagenic ... teratogenic effects",
                        "criterion": "investigational agent effects",
                        "requirement": {
                            "requirement_type": "teratogenicity",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Examples of additional effective methods:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration. If subject had autologous SCT > 3 months prior to the start of registration, any treatment-related toxicity is unresolved (grade > 1)",
                "criterions": [
                    {
                        "exact_snippets": "Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration",
                        "criterion": "prior autologous stem cell transplantation (SCT)",
                        "requirement": {
                            "requirement_type": "time since transplantation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "autologous SCT > 3 months prior to the start of registration ... any treatment-related toxicity is unresolved (grade > 1)",
                        "criterion": "treatment-related toxicity (for patients with autologous SCT > 3 months prior to registration)",
                        "requirement": {
                            "requirement_type": "toxicity resolution",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "autologous SCT > 3 months prior to the start of registration ... any treatment-related toxicity is unresolved (grade > 1)",
                        "criterion": "treatment-related toxicity (for patients with autologous SCT > 3 months prior to registration)",
                        "requirement": {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior autologous stem cell transplantation (SCT) ≤ 3 months prior to registration",
                        "criterion": "prior autologous stem cell transplantation (SCT)",
                        "requirement": {
                            "requirement_type": "time since transplantation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "autologous SCT > 3 months prior to the start of registration ... any treatment-related toxicity is unresolved (grade > 1)",
                                "criterion": "treatment-related toxicity (for patients with autologous SCT > 3 months prior to registration)",
                                "requirement": {
                                    "requirement_type": "toxicity resolution",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "autologous SCT > 3 months prior to the start of registration ... any treatment-related toxicity is unresolved (grade > 1)",
                                "criterion": "treatment-related toxicity (for patients with autologous SCT > 3 months prior to registration)",
                                "requirement": {
                                    "requirement_type": "toxicity grade",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": ""
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Progesterone-only pills [e.g., desogestrel])",
                "criterions": [
                    {
                        "exact_snippets": "Progesterone-only pills [e.g., desogestrel]",
                        "criterion": "progesterone-only pill use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Progesterone-only pills [e.g., desogestrel]",
                        "criterion": "progesterone-only pill use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Age ≥ 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age  18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide",
                "criterions": [
                    {
                        "exact_snippets": "Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide",
                        "criterion": "blood donation",
                        "requirement": {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects must agree not to donate blood while receiving golcadomide, during dose interruptions and for ≥ 28 days following the last dose of golcadomide",
                        "criterion": "blood donation",
                        "requirement": {
                            "requirement_type": "abstinence period",
                            "expected_value": [
                                "while receiving golcadomide",
                                "during dose interruptions",
                                ">= 28 days following the last dose of golcadomide"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) ≥ 1000/mcL (obtained ≤ 14 days prior to registration); growth factor support allowed at physician discretion",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000/mcL (obtained ≤ 14 days prior to registration)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1000/mcL (obtained ≤ 14 days prior to registration)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "timing of measurement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    },
                    {
                        "exact_snippets": "growth factor support allowed at physician discretion",
                        "criterion": "growth factor support",
                        "requirement": {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "growth factor support allowed at physician discretion",
                        "criterion": "growth factor support",
                        "requirement": {
                            "requirement_type": "physician discretion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1000/mcL (obtained \u001e 14 days prior to registration)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1000/mcL (obtained \u001e 14 days prior to registration)",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "timing of measurement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelet count ≥ 75,000/mcL (obtained ≤ 14 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Platelet count ≥ 75,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained ≤ 14 days prior to registration",
                        "criterion": "platelet count measurement date",
                        "requirement": {
                            "requirement_type": "time since measurement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelet count \u001e 75,000/mcL",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "mcL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained \u001e 14 days prior to registration",
                        "criterion": "platelet count measurement date",
                        "requirement": {
                            "requirement_type": "time since measurement",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A negative serum or urine pregnancy test (investigator's discretion) within 24 hours prior to cycle 1 day 1 of study treatment",
                "criterions": [
                    {
                        "exact_snippets": "A negative serum or urine pregnancy test ... within 24 hours prior to cycle 1 day 1 of study treatment",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "A negative serum or urine pregnancy test ... within 24 hours prior to cycle 1 day 1 of study treatment",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "test_type",
                            "expected_value": [
                                "serum",
                                "urine"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "A negative serum or urine pregnancy test ... within 24 hours prior to cycle 1 day 1 of study treatment",
                        "criterion": "pregnancy test result",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 24,
                                "unit": "hours before cycle 1 day 1"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification including patients with diseases listed below with relapsed, progressive and/or refractory disease (Cheson et al. 2014) following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted:",
                "criterions": [
                    {
                        "exact_snippets": "Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification",
                        "criterion": "pathology diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Confirmed pathology diagnosis according to 2016 World Health Organization (WHO) classification",
                        "criterion": "pathology diagnosis",
                        "requirement": {
                            "requirement_type": "classification_system",
                            "expected_value": "2016 World Health Organization (WHO) classification"
                        }
                    },
                    {
                        "exact_snippets": "patients with diseases listed below with relapsed, progressive and/or refractory disease (Cheson et al. 2014)",
                        "criterion": "disease status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "progressive",
                                "refractory"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "following treatment with one or two prior lines of standard therapy, no more than two lines of therapy are permitted",
                        "criterion": "number of prior lines of standard therapy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula (obtained ≤ 14 days prior to registration)",
                "criterions": [
                    {
                        "exact_snippets": "Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained ≤ 14 days prior to registration",
                        "criterion": "creatinine clearance measurement date",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Calculated creatinine clearance  45 ml/min using the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Calculated creatinine clearance  45 ml/min using the Cockcroft-Gault formula",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "ml/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "obtained  14 days prior to registration",
                        "criterion": "creatinine clearance measurement date",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* High grade B-cell lymphoma with MYC and BCL2 translocation",
                "criterions": [
                    {
                        "exact_snippets": "High grade B-cell lymphoma",
                        "criterion": "B-cell lymphoma",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": "high"
                        }
                    },
                    {
                        "exact_snippets": "MYC and BCL2 translocation",
                        "criterion": "genetic translocation",
                        "requirement": {
                            "requirement_type": "genes involved",
                            "expected_value": [
                                "MYC",
                                "BCL2"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Any prior CAR-T or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to registration",
                        "criterion": "prior CAR-T or other T-cell targeting treatment",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to registration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any prior CAR-T or other T-cell targeting treatment (approved or investigational) \u0010 4 weeks prior to registration",
                        "criterion": "prior CAR-T or other T-cell targeting treatment",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to registration"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* NOTE: If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin. This is due to an increased risk of thrombosis in patients treated with golcadomide without prophylaxis",
                "criterions": [
                    {
                        "exact_snippets": "If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin.",
                        "criterion": "ability and willingness to receive anticoagulation therapy",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin.",
                        "criterion": "ability and willingness to receive anticoagulation therapy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "If a patient develops a thrombotic event, they must be able and willing to receive anticoagulation therapy with aspirin 81-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or Warfarin.",
                        "criterion": "ability and willingness to receive anticoagulation therapy",
                        "requirement": {
                            "requirement_type": "therapy options",
                            "expected_value": [
                                "aspirin 81-325 mg daily prophylaxis",
                                "low molecular weight heparin",
                                "factor X inhibitors",
                                "Warfarin"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Ongoing or active infection",
                "criterions": [
                    {
                        "exact_snippets": "Ongoing or active infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Exception: Monoclonal and bispecific antibodies is acceptable",
                "criterions": [
                    {
                        "exact_snippets": "Monoclonal and bispecific antibodies is acceptable",
                        "criterion": "antibody therapy type",
                        "requirement": {
                            "requirement_type": "acceptability",
                            "expected_value": [
                                "monoclonal antibody",
                                "bispecific antibody"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Major surgery ≤ 3 weeks prior to registration",
                "criterions": [
                    {
                        "exact_snippets": "Major surgery ≤ 3 weeks prior to registration",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Major surgery ≤ 3 weeks prior to registration",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia. Patients with a history of deep vein thrombosis (DVT)/pulmonary embolism (PE) or thrombophilia may still participate if they are willing to be on full anticoagulation during treatment. Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses. The rationale for this requirement is that golcadomide therapy is associated with an increased risk of thrombosis. Patients with no history of DVT/PE or thrombophilia are not required to take anticoagulation and/or anti-platelet prophylaxis",
                "criterions": [
                    {
                        "exact_snippets": "History of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia",
                        "criterion": "history of thrombotic events or thrombophilia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients with a history of deep vein thrombosis (DVT)/pulmonary embolism (PE) or thrombophilia may still participate if they are willing to be on full anticoagulation during treatment",
                        "criterion": "willingness to be on full anticoagulation",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses",
                        "criterion": "anticoagulation regimen",
                        "requirement": {
                            "requirement_type": "regimen",
                            "expected_value": [
                                "Warfarin",
                                "factor X inhibitors",
                                "low molecular weight heparin"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Full anticoagulation is defined as Warfarin, factor X inhibitors, or low molecular weight heparin at therapeutic doses",
                        "criterion": "anticoagulation regimen",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": "therapeutic"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens",
                "criterions": [
                    {
                        "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity",
                        "criterion": "co-morbid systemic illnesses",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "other severe concurrent disease",
                        "criterion": "severe concurrent disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "other ... cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study",
                        "criterion": "other cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Co-morbid systemic illnesses or other severe concurrent disease or cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity",
                        "criterion": "co-morbid systemic illnesses",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other severe concurrent disease",
                        "criterion": "severe concurrent disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "other ... cancer which, in the judgment of the investigator, would make the patient inappropriate for entry into this study",
                        "criterion": "other cancer",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Persons who can father a child and are unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide",
                "criterions": [
                    {
                        "exact_snippets": "Persons who can father a child",
                        "criterion": "ability to father a child",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide",
                        "criterion": "donation of semen or sperm",
                        "requirement": {
                            "requirement_type": "willingness to refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to refrain from donating semen or sperm while receiving golcadomide, during dose interruptions, or for ≥ 28 days following the last dose of golcadomide",
                        "criterion": "donation of semen or sperm",
                        "requirement": {
                            "requirement_type": "time period",
                            "expected_value": [
                                "while receiving golcadomide",
                                "during dose interruptions",
                                "for ≥ 28 days following the last dose of golcadomide"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Persons who can father a child unwilling to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or post-ovulation methods] and withdrawal are not acceptable methods of contraception.) or unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy",
                "criterions": [
                    {
                        "exact_snippets": "Persons who can father a child unwilling to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.",
                        "criterion": "willingness to practice complete abstinence",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy",
                        "criterion": "willingness to use a condom during sexual contact with a pregnant person or a PCBP",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy",
                        "criterion": "willingness to use a condom during sexual contact with a pregnant person or a PCBP",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unwilling to use a condom during sexual contact with a pregnant person or a PCBP during treatment and dose interruptions, and for > 28 days following the last dose of golcadomide, even if they have undergone a successful vasectomy",
                        "criterion": "willingness to use a condom during sexual contact with a pregnant person or a PCBP",
                        "requirement": {
                            "requirement_type": "context",
                            "expected_value": [
                                "during treatment",
                                "dose interruptions",
                                "following the last dose of golcadomide"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence [e.g., calendar, ovulation, symptothermal or postovulation methods] and withdrawal are not acceptable methods of contraception) from heterosexual contact during the following time periods related to this study:",
                "criterions": [
                    {
                        "exact_snippets": "Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "number of methods",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "reliable forms"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Persons of childbearing potential (PCBP) unwilling to use two reliable forms of contraception simultaneously",
                        "criterion": "contraception use",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.",
                        "criterion": "abstinence from heterosexual contact",
                        "requirement": {
                            "requirement_type": "practice",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.",
                        "criterion": "abstinence from heterosexual contact",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "complete abstinence"
                        }
                    },
                    {
                        "exact_snippets": "or to practice complete abstinence (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject.",
                        "criterion": "abstinence from heterosexual contact",
                        "requirement": {
                            "requirement_type": "lifestyle alignment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Periodic abstinence [e.g., calendar, ovulation, symptothermal or postovulation methods] and withdrawal are not acceptable methods of contraception",
                        "criterion": "contraception method",
                        "requirement": {
                            "requirement_type": "method exclusion",
                            "expected_value": [
                                "periodic abstinence",
                                "withdrawal"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy, as there is currently no safety data in HIV positive patients",
                "criterions": [
                    {
                        "exact_snippets": "Immunocompromised patients",
                        "criterion": "immunocompromised status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "patients known to be HIV positive and currently receiving antiretroviral therapy",
                        "criterion": "HIV positive status and antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "HIV status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "patients known to be HIV positive and currently receiving antiretroviral therapy",
                        "criterion": "HIV positive status and antiretroviral therapy",
                        "requirement": {
                            "requirement_type": "antiretroviral therapy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Immunocompromised patients",
                        "criterion": "immunocompromised status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "patients known to be HIV positive and currently receiving antiretroviral therapy",
                                "criterion": "HIV positive status and antiretroviral therapy",
                                "requirement": {
                                    "requirement_type": "HIV status",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "patients known to be HIV positive and currently receiving antiretroviral therapy",
                                "criterion": "HIV positive status and antiretroviral therapy",
                                "requirement": {
                                    "requirement_type": "antiretroviral therapy",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Hormonal (birth control pills, injections, implants, levonorgestrel-releasing intrauterine system [IUS], medroxyprogesterone acetate depot injections, ovulation inhibitory",
                "criterions": [
                    {
                        "exact_snippets": "Hormonal (birth control pills, injections, implants, levonorgestrel-releasing intrauterine system [IUS], medroxyprogesterone acetate depot injections, ovulation inhibitory",
                        "criterion": "hormonal contraception",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "birth control pills",
                                "injections",
                                "implants",
                                "levonorgestrel-releasing intrauterine system (IUS)",
                                "medroxyprogesterone acetate depot injections",
                                "ovulation inhibitory"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease [COPD])",
                "criterions": [
                    {
                        "exact_snippets": "Dyspnea at rest due to complications of advanced malignancy or other disease",
                        "criterion": "dyspnea at rest",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Dyspnea at rest due to complications of advanced malignancy or other disease",
                        "criterion": "dyspnea at rest",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "complications of advanced malignancy",
                                "other disease"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease [COPD])",
                        "criterion": "requirement for continuous oxygen therapy",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "requires continuous oxygen therapy (such as interstitial lung disease or chronic obstructive pulmonary disease [COPD])",
                        "criterion": "requirement for continuous oxygen therapy",
                        "requirement": {
                            "requirement_type": "cause",
                            "expected_value": [
                                "interstitial lung disease",
                                "chronic obstructive pulmonary disease (COPD)"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide",
                "criterions": [
                    {
                        "exact_snippets": "For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "duration before starting treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For ≥ 28 days before starting treatment, during treatment and dose interruptions, and for ≥ 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "coverage during treatment and dose interruptions",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "For \u001e 28 days before starting treatment, during treatment and dose interruptions, and for \u001e 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "duration before starting treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For \u001e 28 days before starting treatment, during treatment and dose interruptions, and for \u001e 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "For \u001e 28 days before starting treatment, during treatment and dose interruptions, and for \u001e 28 days after the last dose of golcadomide",
                        "criterion": "time period for specified action(s) relative to golcadomide treatment",
                        "requirement": {
                            "requirement_type": "coverage during treatment and dose interruptions",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subject had prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration. If subject had prior allogeneic SCT > 6 months prior to registration, any treatment-related toxicity is unresolved (grade >1)",
                "criterions": [
                    {
                        "exact_snippets": "prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration",
                        "criterion": "prior allogeneic stem cell transplant (SCT)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration",
                        "criterion": "prior allogeneic stem cell transplant (SCT)",
                        "requirement": {
                            "requirement_type": "conditioning intensity",
                            "expected_value": [
                                "standard",
                                "reduced"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "prior allogeneic SCT with either standard or reduced intensity conditioning ≤ 6 months prior to registration",
                        "criterion": "prior allogeneic stem cell transplant (SCT)",
                        "requirement": {
                            "requirement_type": "time since SCT",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior allogeneic SCT > 6 months prior to registration ... any treatment-related toxicity is unresolved (grade >1)",
                        "criterion": "treatment-related toxicity (for subjects with prior allogeneic SCT > 6 months prior to registration)",
                        "requirement": {
                            "requirement_type": "time since SCT",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "prior allogeneic SCT > 6 months prior to registration ... any treatment-related toxicity is unresolved (grade >1)",
                        "criterion": "treatment-related toxicity (for subjects with prior allogeneic SCT > 6 months prior to registration)",
                        "requirement": {
                            "requirement_type": "toxicity resolution",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "prior allogeneic SCT > 6 months prior to registration ... any treatment-related toxicity is unresolved (grade >1)",
                        "criterion": "treatment-related toxicity (for subjects with prior allogeneic SCT > 6 months prior to registration)",
                        "requirement": {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}